Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

NEPTUNUS
海王

深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8329)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 31 DECEMBER 2024

The board of directors of Shenzhen Neptunus Interlong Bio-technique Company Limited (the "**Company**") hereby announces that the extraordinary general meeting (the "**EGM**") was held on 31 December 2024 during which all the proposed resolutions set out in the notice of the EGM of the Company dated 10 December 2024 (the "**Notice**") in relation to the approval, confirmation and ratification of the form and substance of the supplemental agreement (the "**2023 Supplemental Yidianyao Distribution Agreement**") dated 15 November 2024 and entered into between the Company and Neptunus Yidianyao and all transactions contemplated thereunder and all related issues; the approval, confirmation and ratification of the form and substance of the distribution agreement (the "**2024 Yidianyao Distribution Agreement**") dated 15 November 2024 entered into between the Company and Neptunus Yidianyao and all transactions contemplated thereunder and all related issues; and the approval, confirmation and ratification of the form and substance of the distribution agreement (the "**2024 Pharmaceutical Distribution Agreement**") dated 15 November 2024 entered into between Neptunus Changjian and Neptunus Pharmaceutical and all transactions contemplated thereunder and all related issues were duly passed by way of poll.

Reference is made to the Notice and the circular dated 10 December 2024 of the Company (the "**Circular**"). Unless otherwise defined, terms used herein shall have the same meaning as defined in the Circular.

The EGM of the Company was duly held at 10:00 a.m. on Tuesday, 31 December 2024 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, People's Republic of China (the "**PRC**").

As at the date of the EGM, the total number of shares of the Company in issue was 1,678,000,000 shares (nominal value of RMB0.10 per share), of which 1,252,000,000 shares were domestic shares and 426,000,000 shares were H shares. Amongst all the shareholders, Neptunus Bio-engineering and its associate, Shenzhen Neptunus Oriental Investment Company Limited* ("**Neptunus Oriental**"), collectively hold 1,233,464,500 domestic shares (approximately 73.51% of the total issued shares) of the Company. As stated in the Circular, Neptunus Bio-engineering and its associate are required to abstain from voting at the EGM on the resolutions to approve the 2023 Supplemental Yidianyao Distribution Agreement, 2024 Yidianyao Distribution Agreement and 2024 Pharmaceutical Distribution Agreement and all transactions contemplated thereunder and all related issues due to their interests in the transactions. Accordingly, the total number of shares entitling the shareholders to attend and vote for or against the resolutions at the EGM was 444,535,500 shares. The board of directors of the Company confirms that Neptunus Bio-engineering and its associate, Neptunus Oriental, did abstain from voting on the resolutions in the EGM. Save as disclosed above, no shareholder of the Company was required under the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") to abstain from voting on any of the resolutions at the EGM. There were no shares entitling the shareholder to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 17.47A of the GEM Listing Rules.

There were no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury shares have been exercised at the EGM.

Save as disclosed above, none of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.

The Company's H Share Registrar and Transfer Office in Hong Kong, Tricor Investor Services Limited, was appointed and acted as the scrutineer for vote-taking at the EGM.

All Directors of the Company attended the EGM.

RESULTS OF EGM

The EGM was held at 10:00 a.m. on Tuesday, 31 December 2024 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the PRC. The proposed resolutions as set out in the Notice were duly passed by way of poll. The poll results are as follows:

<table>
<tr><th colspan="2" rowspan="2">Ordinary Resolutions</th><th colspan="2">No. of shares represented by votes cast (percentage of total number of shares represented by votes cast)</th></tr>
<tr><th>For</th><th>Against</th></tr>
<tr><td colspan="4">As more than half (1/2) of the votes from the shareholders who attended and voted at the EGM were cast in favour of the following resolutions, the resolutions were duly passed as ordinary resolutions:</td></tr>
<tr><td>1.</td><td>“THAT

(a) the form and substance of the supplemental agreement (the “2023 Supplemental Yidianyao Distribution Agreement”) dated 15 November 2024 entered into between the Company and 深圳市海王易點藥醫藥有限公司 (Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited*) (a copy of the 2023 Supplemental Yidianyao Distribution Agreement has been produced to the meeting and marked “A” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;

(b) the proposed revision of the Existing Annual Cap to the Revised Annual Cap under the 2023 Supplemental Yidianyao Distribution Agreement for the year ending 31 December 2024 be and is hereby confirmed and approved; and

(c) any one director of the Company (the “Director”) be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2023 Supplemental Yidianyao Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2023 Supplemental Yidianyao Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”</td><td>2,789,500
(100%)</td><td>Nil
(–%)</td></tr>
</table>

Ordinary Resolutions		No. of shares represented by votes cast (percentage of total number of shares represented by votes cast)	
		For	**Against**
2.	“**THAT** (a) the form and substance of the distribution agreement (the “**2024 Yidianyao Distribution Agreement**”) dated 15 November 2024 entered into between the Company and 深圳市海王易點藥醫藥有限公司 (Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited*) (a copy of the 2024 Yidianyao Distribution Agreement has been produced to the meeting and marked “B” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified; (b) the proposed sales caps under the 2024 Yidianyao Distribution Agreement for each of the three years ending 31 December 2025, 2026 and 2027 be and is hereby confirmed and approved; and (c) any one Director be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2024 Yidianyao Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2024 Yidianyao Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”	2,789,500 (100%)	Nil (–%)

<table>
<tr><th colspan="2" rowspan="2">Ordinary Resolutions</th><th colspan="2">No. of shares represented by votes cast (percentage of total number of shares represented by votes cast)</th></tr>
<tr><th>For</th><th>Against</th></tr>
<tr><td>3.</td><td>“THAT

(a) the form and substance of the distribution agreement (the “2024 Pharmaceutical Distribution Agreement”) dated 15 November 2024 entered into between 深圳海王長健醫藥有限公司 (Shenzhen Neptunus Changjian Pharmaceutical Company Limited*) and 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (a copy of the 2024 Pharmaceutical Distribution Agreement has been produced to the meeting and marked “C” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;

(b) the proposed purchase caps under the 2024 Pharmaceutical Distribution Agreement for each of the three years ending 31 December 2025, 2026 and 2027 be and is hereby confirmed and approved; and

(c) any one Director be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2024 Pharmaceutical Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2024 Pharmaceutical Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”</td><td>2,789,500
(100%)</td><td>Nil
(–%)</td></tr>
</table>

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 31 December 2024

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company's website at www.interlong.com.

* *For identification purpose only*